Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions

Abstract

Oxygen-depleted hypoxic regions in the tumour are generally resistant to therapies1. Although nanocarriers have been used to deliver drugs, the targeting ratios have been very low. Here, we show that the magneto-aerotactic migration behaviour2 of magnetotactic bacteria3, Magnetococcus marinus strain MC-1 (ref. 4), can be used to transport drug-loaded nanoliposomes into hypoxic regions of the tumour. In their natural environment, MC-1 cells, each containing a chain of magnetic iron-oxide nanocrystals5, tend to swim along local magnetic field lines and towards low oxygen concentrations6 based on a two-state aerotactic sensing system2. We show that when MC-1 cells bearing covalently bound drug-containing nanoliposomes were injected near the tumour in severe combined immunodeficient beige mice and magnetically guided, up to 55% of MC-1 cells penetrated into hypoxic regions of HCT116 colorectal xenografts. Approximately 70 drug-loaded nanoliposomes were attached to each MC-1 cell. Our results suggest that harnessing swarms of microorganisms exhibiting magneto-aerotactic behaviour can significantly improve the therapeutic index of various nanocarriers in tumour hypoxic regions.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Assessment of the specificity of the MC-1 antibody in HCT116 colorectal xenografts in SCID beige mice.
Figure 2: MC-1 cells are preferentially located in the hypoxic regions of the xenografts.
Figure 3: Penetration of live MC-1 cells with and without magnetic field exposure in HCT116 xenografts following a peritumoral injection.
Figure 4: Superior penetration of MC-1 cells over passive diffusion in HCT116 xenografts demonstrated by two methods.
Figure 5: Targeting ratios of MC-1–LP in HCT116 xenografts.

Similar content being viewed by others

References

  1. Vaupel, P. & Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 26, 225–239 (2007).

    Article  CAS  Google Scholar 

  2. Frankel, R. B., Bazylinski, D. A., Johnson, M. S. & Taylor, B. L. Magneto-aerotaxis in marine coccoid bacteria. Biophys. J. 73, 994–1000 (1997).

    Article  CAS  Google Scholar 

  3. Blakemore, R. P. Magnetotactic bacteria. Science 190, 377–379 (1975).

    Article  CAS  Google Scholar 

  4. Bazilinski, D. A. et al. Magnetococcus marinus gen. nov., sp. nov., a marine, magnetotactic bacterium that represents a novel lineage (Magnetococcaceae fam. nov., Magnetococcales ord. nov.) at the base of the Alphaproteobacteria. Int. J. Syst. Evol. Microbiol. 63, 801–808 (2013).

    Article  Google Scholar 

  5. Bazylinski, D. A., Frankel, R. B. & Jannasch, H. W. Anaerobic magnetite production by a marine, magnetotactic bacterium. Nature 334, 518–519 (1988).

    Article  Google Scholar 

  6. Lefèvre, C. T. et al. Diversity of magneto-aerotactic behaviors and oxygen sensing mechanisms in cultured magnetotactic bacteria. Biophys. J. 107, 527–538 (2014).

    Article  Google Scholar 

  7. Brown, J. M. & Wilson, W. R. Exploiting tumour hypoxia in cancer treatment. Nature Rev. 4, 437–446 (2004).

    CAS  Google Scholar 

  8. Wilson, W. R. & Hay, M. P. Targeting hypoxia in cancer therapy. Nature Rev. Cancer 11, 393–410 (2011).

    Article  CAS  Google Scholar 

  9. Hong, M., Zhu, S., Jiang, Y., Tang, G. & Pei, Y. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated liposomes modified with transferrin. J. Control. Rel. 133, 96–102 (2009).

    Article  CAS  Google Scholar 

  10. Tannock, I. F., Lee, C. M., Tunggal, J. K., Cowan, D. S. M. & Egorin, M. J. Limited penetration of anticancer drugs through tumor tissue. Clin. Cancer Res. 8, 878–884 (2002).

    CAS  Google Scholar 

  11. Patyar, S. et al. Bacteria in cancer therapy: a novel experimental strategy. J. Biomed. Sci. 17, 21 (2010).

    Article  CAS  Google Scholar 

  12. Schüler, D. Formation of magnetosomes in magnetotactic bacteria. J. Molec. Microbiol. Biotechnol. 1, 79–86 (1999).

    Google Scholar 

  13. de Lanauze, D., Felfoul, O., Turcot, J.-P., Mohammadi, M. & Martel, S. Three-dimensional remote aggregation and steering of magnetotactic bacteria microrobots for drug delivery applications. Int. J. Robot. Res. 33, 359–374 (2014).

    Article  Google Scholar 

  14. McDonald, D. M. & Baluk, P. Significance of blood vessel leakiness in cancer. Cancer Res. 62, 5381–5385 (2002).

    CAS  Google Scholar 

  15. Heldin, C.-H., Rubin, K., Pietras, K. & Ostman, A. High interstitial fluid pressure—an obstacle in cancer therapy. Nature Rev. Cancer 4, 806–813 (2004).

    Article  CAS  Google Scholar 

  16. Taherkhani, S., Mohammadi, M., Daoud, J., Martel, S. & Tabrizian, M. Covalent binding of nanoliposomes to the surface of magnetotactic bacteria acting as self-propelled target delivery agents. ACS Nano 8, 5049–5060 (2014).

    Article  CAS  Google Scholar 

  17. Danhier, F., Feron, O. & Préat, V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control Rel. 148, 135–146 (2010).

    Article  CAS  Google Scholar 

  18. Harrison, L. B., Chadha, M., Hill, R. J., Hu, K. & Shasha, D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 7, 492–508 (2002).

    Article  Google Scholar 

  19. Moeller, B. J., Richardson, R. A. & Dewhirst, M. W. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 26, 241–248 (2007).

    Article  CAS  Google Scholar 

  20. Polyak, B. & Friedman, G. Magnetic targeting for site-specific drug delivery: applications and clinical potential. Expert Opin. Drug Delivery 6, 53–70 (2009).

    Article  CAS  Google Scholar 

  21. Rotariu, O. & Strachan, N. J. C. Modelling magnetic carrier particle targeting in the tumor microvasculature for cancer treatment. J. Magn. Magn. Mater. 293, 639–646 (2005).

    Article  CAS  Google Scholar 

  22. Martel, S. et al. Automatic navigation of an untethered device in the artery of a living animal using a conventional clinical magnetic resonance imaging system. Appl. Phys. Lett. 90, 114105 (2007).

    Article  Google Scholar 

  23. Dreyfus, R. et al. Microscopic artificial swimmers. Nature 437, 862–865 (2005).

    Article  CAS  Google Scholar 

  24. Akin, D. et al. Bacteria-mediated delivery of nanoparticles and cargo into cells. Nature Nanotech. 2, 441–449 (2007).

    Article  CAS  Google Scholar 

  25. Jain, R. K. & Forbes, N. S. Can engineered bacteria help control cancer? Proc. Natl Acad. Sci. USA 98, 14748–14750 (2001).

    Article  CAS  Google Scholar 

  26. Schübbe, S. et al. Complete genome sequence of the chemolithoautotrophic marine magnetotactic coccus strain MC-1. Appl. Environ. Microbiol. 75, 4835–4852 (2009).

    Article  Google Scholar 

Download references

Acknowledgements

This project was initially supported in part by the Canada Research Chair (CRC) Tier 2 in Micro/Nanosystem Development, Fabrication and Validation and by grants from the National Sciences and Engineering Research Council of Canada (NSERC) and the Province of Québec. This work was primarily supported by the Québec Consortium for Drug Discovery (CQDM) and in part by the Research Chair of École Polytechnique in Nanorobotics, Mitacs, and later by the CRC Tier 1 in Medical Nanorobotics. The magnetotaxis system was built with financial help from the Canada Foundation for Innovation (CFI). Preliminary in vivo results were obtained with the financial help of the US National Institutes of Health (NIH) grant no. R21EB007506 from the National Institute of Biomedical Imaging and Bioengineering. The authors thank J. Caron from CQDM for her involvement in the coordination of the project. R. Gladue from Pfizer, R. M. Garbaccio from Merck & Co. and C. Reimer from AstraZeneca R&D are also thanked for their guidance and insights from the pharmaceutical industry. C.C. Tremblay (NanoRobotics Lab.) helped in determining the number of bacteria in samples and T. Johns (Biomat'x, McGill University) in the preparation of liposomes. The authors thank J. Hinsinger (University of Montreal (UdM), Institute for Research in Immunology and Cancer (IRIC)) and the histological team (UdM, IRIC) for tumour histology preparation and D. Gingras (UdM, IRIC) for transmission electron microscopy.

Author information

Authors and Affiliations

Authors

Contributions

S.M. acted as principal investigator, wrote the paper with assistance from O.F., M.M., D.R., S.T. and N.B. and developed the general principles and methods. G.B. and T.V. provided clinical insights. O.F., M.M., S.T., Y.Z.X., D.d.-L., D.L. and D.H. performed the experiments with tumour-bearing animals. S.J., Y.Z.X. and D.H. carried out the IV injections, processed all blood and tissues for analysis and analysed the samples. L.G. performed immunohistochemistry, immunofluorescence and histopathological evaluations. N.K. and M.M., assisted by M.A., acted as project managers. M.M. and O.F. performed the experiments for the preliminary in vivo proofs of concept. O.F. designed the experimental platform. D.d.-L. tested the magnetotactic control process, which was executed by D.L. M.L. and S.E. synthesized the liposomes. M.T. and S.T. attached the liposomes to the MC-1 cells. M.M. cultivated and prepared the bacteria for injection. M.M., D.R., G.B., L.G., N.B. and S.M. made revisions to the manuscript and figures. Y.Z.X. and D.H. coordinated the implantations of tumour xenografts. D.L. developed and calibrated the MC-1 counting software.

Corresponding author

Correspondence to Sylvain Martel.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information

Supplementary information (PDF 1038 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Felfoul, O., Mohammadi, M., Taherkhani, S. et al. Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions. Nature Nanotech 11, 941–947 (2016). https://doi.org/10.1038/nnano.2016.137

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nnano.2016.137

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research